Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Marinus Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Marinus Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 60.4% bzw. 42.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 64.6% pro Jahr wachsen soll.

Wichtige Informationen

60.4%

Wachstumsrate der Gewinne

64.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	42.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	17 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08

Recent updates

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

May 11

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

Apr 16

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 08

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Dec 22

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

Nov 04

Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow

May 26

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:MRNS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	113	-28	36	N/A	7
12/31/2025	58	-78	-59	-73	11
12/31/2024	39	-120	-100	-100	11
3/31/2024	28	-145	-114	-114	N/A
12/31/2023	31	-141	-118	-118	N/A
9/30/2023	31	-134	-113	-113	N/A
6/30/2023	26	-29	-119	-117	N/A
3/31/2023	22	-35	-128	-127	N/A
12/31/2022	25	-20	-115	-113	N/A
9/30/2022	20	-14	-115	-113	N/A
6/30/2022	28	-105	-80	-78	N/A
3/31/2022	28	-91	-69	-67	N/A
12/31/2021	15	-99	-58	-55	N/A
9/30/2021	15	-88	-52	-50	N/A
6/30/2021	5	-84	-71	-70	N/A
3/31/2021	4	-76	-63	-63	N/A
12/31/2020	2	-76	-61	-61	N/A
9/30/2020	0	-74	-61	-61	N/A
6/30/2020	N/A	-72	-58	-58	N/A
3/31/2020	N/A	-69	-51	-51	N/A
12/31/2019	N/A	-54	-49	-49	N/A
9/30/2019	N/A	-49	-42	-42	N/A
6/30/2019	N/A	-46	-37	-36	N/A
3/31/2019	N/A	-43	-34	-33	N/A
12/31/2018	N/A	-37	-28	-28	N/A
9/30/2018	N/A	-31	-23	-23	N/A
6/30/2018	N/A	-24	-20	-19	N/A
3/31/2018	N/A	-19	-18	-18	N/A
12/31/2017	N/A	-19	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-20	N/A
6/30/2017	N/A	-22	N/A	-24	N/A
3/31/2017	N/A	-27	N/A	-26	N/A
12/31/2016	N/A	-29	N/A	-25	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-29	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-22	N/A
12/31/2015	N/A	-25	N/A	-20	N/A
9/30/2015	N/A	-21	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-14	N/A
3/31/2015	N/A	-17	N/A	-11	N/A
12/31/2014	N/A	-13	N/A	-9	N/A
9/30/2014	N/A	-12	N/A	-10	N/A
6/30/2014	N/A	-12	N/A	-8	N/A
3/31/2014	N/A	-11	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MRNS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MRNS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MRNS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MRNSDie Einnahmen des Unternehmens (42.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: MRNSDie Einnahmen des Unternehmens (42.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von MRNS in 3 Jahren voraussichtlich hoch sein wird

Marinus Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$1.98 loss, revenue downgraded

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

Price target decreased by 49% to US$10.44

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Recent updates

Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program

Consensus EPS estimates upgraded to US$1.98 loss, revenue downgraded

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Marinus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Price target decreased by 49% to US$10.44

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%

New major risk - Share price stability

Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial

Marinus Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

CEO, President & Chairman exercised options to buy US$452k worth of stock.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Full year 2023 earnings: EPS and revenues miss analyst expectations

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Marinus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

New major risk - Revenue and earnings growth

Marinus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.53 loss in 1Q 2022)

Price target decreased by 7.8% to US$22.60

New minor risk - Share price stability

Marinus Pharmaceuticals, Inc. Announces European Commission Approval of ZTALMY (Ganaxolone) Oral Suspension for Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder in Patients Two to 17 Years of Age

Marinus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Marinus Pharmaceuticals, Inc. Receives Positive CHMP Opinion for ZTALMY®? (ganaxolone) for the Adjunctive Treatment of Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Appoints Sarah Noonberg as Member of the Board

Consensus revenue estimates increase by 11%

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: US$0.51 loss per share (vs US$2.69 loss in FY 2021)

Marinus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Marinus Pharmaceuticals, Inc. Appoints Steve Pfanstiel as Chief Operating Officer

Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Consensus forecasts updated

Marinus Pharmaceuticals, Inc. Announces Board Changes

Price target decreased to US$25.11

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Marinus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Consensus revenue estimates fall by 16%

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Consensus revenue estimates increase by 59%

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY (Ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Marinus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Dynamic Index

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

Consensus revenue estimates increase by 38%

Marinus Pharmaceuticals, Inc. Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Revisiting Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$30.56

Marinus Pharmaceuticals, Inc. Announces Publication in the Lancet Neurology of Ztalmy® (Ganaxolone) Phase 3 Marigold Trial Results

Marinus Pharmaceuticals, Inc. announced that it has received $1.230085 million in funding